Merck buys German immuno-oncology company in deal valued at up to $554M

Merck entered into a deal Wednesday to buy a German cancer immunotherapy company in a deal valued at up to $554 million. Merck will make an upfront payment of $137.3 million to Munich-based Rigontec. The deal also includes an additional $417 million in potential milestone payments. The transaction is subject to certain closing conditions. Immunotherapy is a rapidly expanding field in cancer therapy that seeks to im prove the ability of a patient’s own immune system to identify and destroy tumors. Rigontec’s…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

In this report, we propose that the molecular mechanisms of beneficial actions of CR should be classified and discussed according to whether they operate under rich or insufficient energy resource conditions. Future studies of the molecular mechanisms of the beneficial actions of CR should also consider the extent to which the signals/factors involved contribute to the anti-oxidative, anti-inflammatory, anti-tumor and other CR actions in each tissue or organ, and thereby lead to anti-aging and prolongevity. RNA Interference of ATP Synthase Subunits Slows Aging in Nematodes
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Immunotherapy,Volume 10, Issue 14, Page 1265-1284, October 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
Development of T-cell based immunotherapies for the treatment of various cancers has been challenged for decades by the lack of target antigens that are only expressed by cancer cells and not normal tissues. KK-LC-1 belongs to a family of tumor antigens known as cancer-testis antigens, which have restricted expression in immune-privileged germ cells and various cancers, and not in normal life-essential tissues. This makes KK-LC-1 an attractive target for T-cell based anti-cancer therapies.Inventors from the National Cancer Institute ’sExperimental Transplantation and Immunology Branch (NCI ETIB) have discovered two n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Authors: Schanz M, Schricker S, Pfister F, Alscher MD, Kimmel M Abstract Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects. Direct toxicit...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
The 2018 Nobel Prize in physiology or medicine recognizes James P. Allison and Tasuku Honjo for “their discovery of cancer therapy by inhibition of negative immune regulation.” This is a developing story. It will be updated.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
Clinical progress in cancer immunotherapy has been slow; however, within the last 5  years, breakthrough successes have brought immunotherapy to the forefront in cancer therapy. Promising results have been observed in solid tumors and hematologic malignancies. Most treatment modalities have shown limited efficacy as monotherapy. The complex nature of cancer and the immunosuppressi ve microenvironment emphasizes the need to personalize immunotherapy by manipulating the patient’s own immune system. For successful and long-lasting cure of cancer, a multimodal approach is essential, combining antitumor cell therapy ...
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: These results support the clinical use of consensus MAGE-A immunogens with the capacity to target multiple MAGE-A family members to prevent tumor immune escape. PMID: 30262507 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractIn recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. In this context, neutrophils were shown to possess both pro- and anti-tumor properties. To exert their anti-tumor effect, neutrophils need to migrate towards, and form physical contact with tumor cells. Neutrophils secrete H2O2 in a contact-dependent mechanism, thereby inducing a lethal Ca2+ influx via the activation of the H2O2-dependent TRPM2 Ca2+ channel. Here, we explored the mechanism regulating neutrophil chemoattraction to tumor cells. Interestingly, we found that TRPM2 plays a role in this context as ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Germany Health | Health Management | Immunotherapy | Merck | Pharmaceuticals